cAMP prevents antibody-mediated thrombus formation in COVID-19 1

2	
3	Jan Zlamal ^{1*} , Karina Althaus ^{1,2*} , Hisham Jaffal ¹ , Lisann Pelzl ¹ , Anurag Singh ¹ , Andreas
4	Witzemann ¹ , Helene Häberle ³ , Valbona Mirakaj ³ , Peter Rosenberger ³ and Tamam
5	Bakchoul ^{1,2}
6	
7 8	¹ Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen
9	² Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen
10	³ Department of Anesthesiology and Intensive Care Medicine, University Hospital of
11	Tuebingen
12	* Indicates equal contribution
13	
14	Running title: cAMP prevents antibody-induced procoagulant platelets
15	Tables: 1
16	Figures: 10
17	
18	Key words: procoagulant platelet, Fc-gamma-receptor IIA, COVID-19, cAMP
19	
20	Corresponding author:
21 22 23 24 25 26 27 28	Tamam Bakchoul , MD University Hospital of Tuebingen Otfried-Müller-Straße 4/1 72076 Tübingen Tel: +49-(0)7071 / 29-81601, Fax: +49-(0)7071 / 29-5240 E-mail: <u>tamam.bakchoul@med.uni-tuebingen.de</u>
29	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Key points

- 31 Fc-gamma-receptor IIA mediated PS externalization on the PLT surface
- 32 triggers increased thrombus formation
- Inductors of cAMP inhibit antibody-mediated thrombus formation and may
- 34 have potential therapeutic advantage in COVID-19
- 35

36 Abstract

37 Thromboembolic events are frequently reported in patients infected with the SARS-38 CoV-2 virus. However, the exact mechanisms of thromboembolic events remain 39 elusive. In this work, we show that immunoglobulin G (IgG) subclass in patients with COVID-19 trigger the formation of procoagulant PLTs in a Fc-gamma-RIIA (FcyRIIA) 40 41 dependent pathway leading to increased thrombus formation in vitro. Most 42 importantly, these events were significantly inhibited via FcyRIIA blockade as well as 43 by the elevation of PLTs' intracellular cyclic-adenosine-monophosphate (cAMP) 44 levels by the clinical used agent lloprost. The novel findings of FcyRIIA mediated prothrombotic conditions in terms of procoagulant PLTs leading to higher thrombus 45 46 formation as well as the successful inhibition of these events via lloprost could be 47 promising for the future treatment of the complex coagulopathy observed in COVID-19 disease. 48

50 Introduction

51 Infection with SARS-CoV-2 has been shown to be associated with abnormalities in 52 the coagulation system with an increased incidence of thromboembolic events in 53 small vessels leading to higher mortality (1-3). Accumulating evidence suggests 54 upregulated release of inflammatory cytokines and increased interaction between 55 different actors of innate and adaptive immunity as the main causes for the 56 prothrombotic environment observed in COVID-19 disease (4). Moreover, a significant number of reports described platelet (PLT) hyperactivity in patients with 57 COVID-19, which is assumed to contribute to prothrombotic conditions (5, 6). 58 59 Procoagulant PLTs, predominantly generated at the outer side of the growing 60 thrombus, are increasingly recognized to link primary with secondary haemostasis (7-61 10). The latter is mainly executed by negatively charged membrane phospholipids externalized on the PLT surface. This unique feature of procoagulant PLTs enables 62 the assembly of tenase as well as prothrombinase complexes leading to high 63 thrombin burst, increased fibrin deposition and thrombus formation (11). Recently, we 64 showed that PLTs from patients with severe COVID-19 infection express a 65 procoagulant phenotype. Immunoglobulin G (IgG) fractions were found to be 66 67 responsible for the COVID-19 induced procoagulant PLTs (Althaus et al. accepted). In the current study, we investigate the time course of the generation of 68 antibody- induced procoagulant PLTs as well as the mechanisms leading to 69 70 alterations in the PLT phenotype in COVID-19. We observed that IgG fractions from 71 severe COVID-19 patients induce increased thrombus formation in an Fc-gamma 72 RIIA (FcyRIIA) dependent manner. More importantly, we were able to show that 73 cyclic-adenosine-monophosphate (cAMP) elevation in PLTs prevents COVID-19 74 antibody-induced procoagulant PLT generation as well as clot formation.

75 Materials and Methods

76 Patients and sera

77 Experiments were performed using leftover serum material from COVID-19 patients 78 who were referred to our laboratory between March and June 2020. The diagnosis of 79 SARS-CoV-2 infection was confirmed by real time PCR on material collected by 80 nasal swabs. Sera from ICU non-Covid-19 patients with postoperative sepsis were 81 collected to serve as ICU control group. Additionally, sera were collected from 82 healthy blood donors at the Blood Donation Centre Tuebingen after written 83 consensus was obtained to establish cutoff values when appropriate. Serum samples 84 were stored at -80°C and thawed at room temperature prior to the performed 85 experimental procedure. All sera were heat-inactivated at 56°C for 30 minutes (min), 86 which was followed by a centrifugation step at 5000xg. The spun-down was discarded and supernatants were handled as described in the following sections. 87

88 IgG preparation

89 IgG fractions were isolated by the use of a commercially available IgG-purification-kit 90 (MelonTM-Gel IgG Spin Purification Kit, Thermo Fisher Scientific, Waltham, USA) and 91 used as recommended by the manufacturer. In brief, heat inactivated serum was 92 diluted 1:10 in purification buffer and incubated with the kit specific Gel IgG 93 Purification Support over four cycles for 10 min. Subsequently, periodically performed 94 centrifugation steps through a 10 µm pore size filter tube were performed for 1 min at 95 5000xg. The flow throw was collected into 100 kDa-pore sized centrifugal filters 96 (Amicon Ultra-4, Merck Millipore, Cork, Ireland) with subsequent concentration to the 97 initial volume of the used serum sample via centrifugation (10-15 min, 2000xg, 4°C, 98 with brake). Afterwards, IgG concentrations were measured at a mass extinction

- 99 coefficient of 13.7 at 280 nm wavelength using a NanoDrop One spectrophotometer
- 100 (VWR, Bruchsal, Germany). IgG purity was verified using Coomassie staining
- 101 (Abcam, Cambridge, UK).

102 **Preparation of washed platelets**

103 Washed platelets (wPLTs) were prepared from venous blood samples as described previously (12). Briefly, whole blood from healthy donors was withdrawn by cubital 104 105 venipuncture into acidic-dextrose containing vacutainers (Becton-Dickinson, 106 Plymouth, UK) and allowed to rest for 45 min at 37°C. After centrifugation (20 min, 107 120xg, room temperature [RT], no brake) PLT-rich-plasma (PRP) was gently 108 separated and supplemented with apyrase (5 µL/mL, Sigma-Aldrich, St. Louis, USA) 109 and prewarmed ACD-A (111 µL/mL, Terumo BCT, Inc., Lakewood, USA). After an 110 additional centrifugation step (7 min, 650xg, RT, no brake), the PLT pellet was 111 resuspended in 5 mL of wash-solution (modified Tyrode buffer: 5 mL bicarbonate 112 buffer, 20 percent (%) bovine serum albumin, 10% glucose solution [Braun, 113 Melsungen, Germany], 2.5 U/mL apyrase, 1 U/mL hirudin [Pentapharm, Basel, 114 Swiss], pH 6.3) and allowed to rest for 15 min at 37°C. Following final centrifugation (7 min, 650xg, RT, no brake) wPLTs were resuspended in 2 mL of resuspension-115 116 buffer (50 mL of modified Tyrode buffer, 0.5 mL of 0.1 M MgCl2, 1 mL of 0.2 M 117 CaCl2, pH 7.2) and adjusted to 300x10⁹ PLTs/L after the measurement at a Cell-Dyn 118 Ruby hematological analyzer (Abott, Wiesbaden, Germany) was performed. For 119 calcium chelation experiments, the PLT pellet was resuspended with resuspension-120 buffer without the supplementation of calcium (50 mL of modified Tyrode buffer, 0.5 121 mL of 0.1 M MgCl2, pH 7.2).

122 Treatment of wPLTs with ICU COVID-19 sera/IgG

wPLTs ($7.5x10^6$) were supplemented with 5 μ L serum/IgG from ICU COVID-19

124 patients or control serum/IgG and incubated for 1.5 hours (hs) at RT under rotating

125 conditions. Afterwards, samples were washed once (7 min, 650xg, RT, no brake),

126 resuspended in 100 µL of phosphate buffered saline (PBS, [Biochrom, Berlin,

127 Germany]) and further handled as described in the following sections.

128 Detection of phosphatidylserine exposure

129 To assess externalization of phosphatidylserine (PS) on the PLT surface after

130 antibody treatment, 10 µL of PLT suspension were transferred into 100 µL of Hank's

131 balanced salt solution (HBSS), (137 mM NaCl, 1.25 mM CaCl₂, 5.5 mM glucose,

132 [Carl-Roth, Karlsruhe, Germany]) and incubated with 1 µL Annexin V-FITC

133 (Immunotools, Friesoythe, Germany) for 30 min at RT in the dark. To induce the

134 maximal externalization of PS on the PLT surface, wPLTs were incubated with

ionomycin (Sigma-Aldrich, St. Louis, USA, [5 µM, 15 min at RT]). Afterwards, PLTs

136 were filled up with HBSS to a final volume of 500 µL and acquired at a flow cytometer

137 ([FC], Navios, Beckman-Coulter, Brea, USA).

PLTs were gated based on their characteristic forward scatter (FSC) vs. side scatter (SSC) properties as well as CD41a and CD42a expression (anti-CD41a-PC5 and anti-CD42a-PerCP, both BD, San Jose, USA), respectively. Test results were analyzed as fold increase of the percentage PS positive PLTs compared to PLTs that were incubated with serum/IgG from healthy individuals.

Determination of changes in the inner-mitochondrial-transmembrane potential (ΔΨ)

145 Changes of the mitochondrial inner transmembrane potential ($\Delta \Psi$) induced by ICU

146 COVID-19 sera/IgG were analyzed by FC, as previously reported (13). Briefly, after

treatment with IgG/serum from ICU COVID-19 patients, wPLTs (~2x10⁶) were 147 148 incubated with a final concentration of 10 µM tetramethylrhodamine, ethyl ester 149 (TMRE, Abcam, Cambridge, UK) for 30 min at RT in the dark. Carbonyl cyanide 4-150 (trifluoromethoxy) phenylhydrazone (FCCP, Abcam, Cambridge, UK) which is an uncoupler of mitochondrial oxidative phosphorylation served as positive control in 151 152 each experiment. After staining with TMRE, PLTs were filled up with PBS to a final 153 volume of 500 μ L and immediately analyzed by FC. Changes in the $\Delta\Psi$ were 154 determined in gated PLTs as percentage of TMRE negative events and normalized to 155 PLTs that were treated with serum/IgG from healthy controls.

156 **Phenotyping of different PLT-populations**

ICU COVID-19 serum/lgG-mediated procoagulant changes (PS/CD62p-double 157 158 positive) were assessed in some experiments using a triple staining. Briefly, 10 µL 159 (~1x10⁶) of the resuspended PLT suspension were transferred into 10 µL of HBSS 160 and incubated with 1 µL anti-CD62p-APC (BD, San Jose, USA), 1 µL Annexin-FITC 161 (Immunotools, Friesoythe, Germany) and 1 µL anti-CD42a-PerCP (BD, San Jose, USA) for 15 min at RT in the dark. PLTs treated with thrombin receptor activating 162 peptide (TRAP-6, [20 µM, 30 min at RT]) and ionomycin (5 µM, 15 min at RT, [both 163 164 Sigma-Aldrich, St. Louis, USA]) served as positive controls. Afterwards, PLTs were resuspended with HBSS to a final volume of 500 µL and immediately assessed via 165 166 FC. In selected experiments that were designed to investigate the impact of calcium 167 on cell signalling, PLT PS externalization was assessed by the use of the calcium independent marker lactadherin. 1 µL of lactadherin-FITC (Haematologic 168 169 Technologies, Essex Junction, USA) was incubated with wPLTs as for Annexin-FITC 170 for 15 min at RT, in the dark, and the PLT suspension filled up to final volume of 500 µL with PBS prior to FC analysis. 171

172 Western blot analysis of caspase 3 cleavage

173 Protein levels of cleaved-caspase 3 were determined by western blot. After serum/IgG incubation, cells were washed with PBS for 7 min, 700xg at 4°C. 174 175 Subsequently, the pellet was resuspended in 100 µL of ice-cold RIPA lysis buffer containing HALT[™] protease and phosphatase inhibitor-cocktail (both ThermoFisher 176 177 Scientific, Paisley, UK). Protein concentrations were determined using the NanoDrop 178 One spectrophotometer (VWR, Bruchsal, Germany). 100 µg of protein was solubilized in sample buffer (Invitrogen[™], Carlsbad, USA) at 95°C for 10 min. 179 Proteins were separated by electrophoresis using 12% SDS-PAGE gels in glycine-180 181 tris buffer. Thereafter, probes were transferred to polyvinylidene difluoride (PVDF) 182 membranes (0.45 µm, Merck, Tullagreen, Ireland). Afterwards, membranes were blocked with 5% milk in tris-buffered saline (TBS-T, 20 mM Tris, 140 mM NaCl, 0.1% 183 184 Tween, pH 7.6) at RT for 1 h. Membranes were then incubated with primary anti-185 human cleaved-caspase 3 antibody (1:1000, Abcam, Cambridge, UK) and antihuman alpha-tubulin (1:1000, Cell Signaling Technology, Danvers, USA) at 4°C 186 187 overnight. After washing with TBS-T buffer, the membranes were incubated with the appropriate secondary anti-rabbit or anti-mouse antibody conjugated with IRDye[®]680 188 189 / IRDye[®]800 (1:3000, LI-COR[®], Lincoln, USA) for 1 h at RT. Protein bands were 190 detected after additional washes (TBS-T) with Odyssey infrared imaging system (LI-191 COR[®], Lincoln, USA). Western blots were analyzed by ImageJ software (NIH, 192 Bethesda, USA). The results are shown as the ratio of total cleaved-caspase 3 to 193 procaspase 3 (full fragment) and normalized to wPLTs that were treated with healthy 194 control serum/IgG.

195 Assessment of the mechanisms of antibody-mediated effects on PLTs

196 75 µL wPLTs were pretreated with the FcyRIIA blocking monoclonal antibody (moAb) anti-CD32 (5 µL moAb IV.3; stemcell[™] technologies, Vancouver, Canada) for 45 min 197 at 37°C prior to serum/IgG treatment. A monoclonal isotype (moAb) served as 198 199 vehicle control ([SC-2025], Santa Cruz Biotechnology, Dallas, USA). 200 For the chelation of extracellular calcium, the non-membrane permeable chelator of extracellular calcium EGTA (Ethyleneglycol-bis(2-aminoethylether)-201 202 N,N,N',N'-tetraacetic acid, 1 mM, 5 min at 37°C [Sigma Aldrich, St. Louis, USA]) was 203 used. 204 For the depletion of calcium in the inner compartment of PLTs, the intracellular 205 chelator of calcium BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-206 tetraacetic acid tetrakis(acetoxymethyl) ester, 20 µM, 15 min at 37°C, [Selleck,

207 Houston, USA]) was used.

To investigate the effect of increased intracellular levels of cAMP, wPLTs were
pretreated with the adenylate cyclase (ADC) inducers Forskolin (2.25 μM) and
Iloprost (20 nM, both Sigma-Aldrich, St. Louis, USA) prior to the incubation with
sera/lgGs from ICU COVID-19 patients.

212 Investigations of antibody-mediated thrombus formation

To assess the impact of ICU COVID-19 IgG-induced effects on clot formation, an ex
vivo model for thrombus formation was established. A microfluidic system (BioFlux,
Fluxion Biosciences, Alameda, USA) was used at a shear rate of 1500⁻¹ (60 dyne)
according to the recommendations of the ISTH standardization committee for
biorheology (14). Briefly, microfluidic channels were coated with collagen (100
µg/mL, Collagen Horm, Takeda, Linz, Austria) overnight at 4°C and blocked with

219 2.5% of human serum albumin (HSA, Kedrion, Barga, Italy) 1 h before perfusion at220 RT.

221 Whole blood samples of healthy individuals of blood group O were collected into 222 hirudin containing monovettes (Sarstedt, Nuembrecht, Germany) and allowed to rest 223 for 30 min at RT. After splitting the whole blood into aliquots of 200 µL, PRP was 224 prepared via centrifugation (20 min, 120xg, at RT, no break). Afterwards, 45 µL of the supernatant PRP was gently separated and incubated with 5 µL of control or ICU 225 226 COVID-19 IgG fractions and incubated for 90 min at RT under rotating conditions. 15 min prior to the end of the incubation period, Calcein-FITC (4 µM, [Thermo Scientific, 227 228 Eugene, Oregon, USA]) was added to each sample. Subsequently, PRP was gently added back to reconstitute whole blood samples. 229

When indicated, the separated PRP was pretreated with moAb IV.3 or moAb
isotype control at a concentration of 20 µg/mL for 30 min at RT. For cAMP induction,
PRP was pretreated with Iloprost (20 nM) or vehicle control (5 min, 37°C) prior to IgG
incubation.

Finally, reconstituted whole blood samples were run at a shear rate of 1500s⁻¹ (60 dyne) for a maximum of 5 min. Immunofluorescence and bright field images were taken from 3-5 randomly chosen microscopic fields (x20, Olympus IX73, Olympus GmbH, Hamburg, Germany). Clot formation was assessed by measuring the % of surface area coated by thrombus (SAC) of 3-5 images via ImageJ (NIH, Bethesda, USA) and normalized to the whole area.

240 Statistical analysis

Statistical analyses were performed using GraphPad Prism 7 (La Jolla, USA). T-test
was used to analyze normally distributed results. Non-parametric test (Mann-Whitney
test) was used when data failed to follow a normal distribution as assessed by

- 244 D'Agostino and Pearson omnibus normality test. Group comparison was performed
- using the Wilcoxon rank-sum test and the Fisher exact test with categorical variables.
- A p-value <0.05 was assumed to represent statistical significance.

247 *Ethics*

- 248 Studies involving human material were approved by the Ethics Committee of the
- 249 Medical Faculty, Eberhard-Karls University of Tuebingen, Germany, and were
- 250 conducted in accordance with the declaration of Helsinki.

251 **Results**

252 Patient characteristics

Sera from 26 ICU COVID-19 patients were enrolled in this study between March the 253 1st and June the 16th 2020. 21 of these ICU COVID-19 patients were included in a 254 previous study (Althaus et al. accepted). The mean age of ICU COVID-19 patients 255 256 was 58 years (range: 29-88 years). 20/30 (67%) patients had known risk factors for 257 severe COVID-19 infection as described previously (15), including hypertension 258 18/30 (60%), obesity 6/30 (20%), coronary artery disease 4/30 (13%) and diabetes 259 mellitus 6/30 (20%). Elevated D-Dimer levels were detected in all patients (median, 260 range: 3.4 mg/dL, 0.9-45.0 mg/dL) and thrombosis was diagnosed in 13/30 (43%) 261 patients. Longitudinal blood samples were available from four COVID-19 patients 262 who were first admitted to normal ward and later to the ICU for mechanical 263 ventilation. As ICU control group, 5 patients who were admitted to ICU due to non-264 COVID-19 related causes were included in this study.

Sera from ICU COVID-19 patients induce progressive increase of procoagulant PLTs

To investigate whether sera of ICU COVID-19 patients have the potential to induce 267 268 an increased $\Delta \psi$ depolarization as well as PS externalization on the PLT surface, 269 wPLTs from healthy individuals were incubated with sera from 26 ICU COVID-19 270 patients with a severe course of disease as well as 5 ICU non-COVID-19 patients. 271 Based on the calculated cuttoffs (mean+2xSD of healthy controls), 19/26 (73%) sera 272 from patients with severe COVID-19 disease induced significantly higher $\Delta \psi$ depolarization in PLTs from healthy donors compared to ICU controls (FI in % Au 273 274 depolarization±SEM: 6.10±1.12 vs. 0.67±0.10, p value <0.0001, Fig. 1 A). In addition,

significantly higher PS externalization was observed when ICU COVID-19 sera were
incubated with PLTs compared to ICU control sera (FI in % PS±SEM: 2.12±0.19 vs.
1.12±0.08, p value <0.0001, Fig. 1 B).

278 Next, we sought to investigate the time course of the observed changes in both markers. Longitudinal blood samples were available from four ICU COVID-19 279 280 patients. Sera were collected at hospital admission (normal ward or ICU) and during 281 a follow up period at ICU for up to 14 days. As shown in Fig. 1 C-F, sera from ICU 282 COVID-19 patients induced significant changes in $\Delta \psi$ depolarization, PS 283 externalization and caspase 3 cleavage as clinical manifestation worsen requiring 284 admission to ICU. Of note, antibody-induced changes peaked within day 3 and 7 of 285 the ICU stay (FI in % $\Delta \psi$ depolarization±SEM: 3.71±0.72, p value 0.0070; and % PS 286 externalization ±SEM: 4.80±1.11, p value <0.0001, respectively, Suppl. Fig. 1). 287 These findings were further supported by WB analyses, as PLTs incubated with the 288 corresponding ICU COVID-19 serum induced caspase 3 cleavage in similar kinetic 289 (Ratio of cleaved caspase 3/procaspase 3 normalized to control±SEM: 4.84±0.45, p 290 value 0.0035, Fig. 1 E+F). Notably, the rise of PLT markers was associated with 291 increasing levels of detected IgGs against the spike S protein of SARS-CoV-2 in the 292 corresponding ICU COVID-19 patients' follow up sera but not in the total IgG 293 contents of isolated IgG fractions (Suppl. Fig. 2 A and B, respectively). Moreover, 294 declining PLT-counts were observed as $\Delta \psi$ depolarization as well as PS 295 externalization increased, vice versa (Suppl. Fig. 3 A and B, respectively).

IgGs from severe COVID-19 trigger procoagulant PLTs with increased ability to form blood clots

To further verify the impact of sera from severe COVID-19 patients on PLTs, the expression of the alpha granule release and PLT activation marker CD62p was

300	analyzed in two colour FC in parallel to PS. FC analyses revealed that IgG fractions
301	from severe COVID-19 patients induce remarkable changes in the PLT SSC and
302	FSC (Fig. 2.1. A+C), as well as in the distribution of CD62p/PS positivity (Fig. 2.1.
303	B+D). In contrast, the PLT population was almost non-affected after incubation with
304	IgGs from healthy controls (HCs) or ICU non-COVID-19 control patients. Overall,
305	higher percentage of double positive events was observed after incubation with IgGs
306	from ICU COVID-19 patients compared to ICU and to HCs (% CD62p/PS positive
307	PLTs±SEM: 31.63±3.86 vs. 4.04±1.16, p value 0.0007; and vs. 2.88±0.52, p value
308	<0.0001, respectively, Fig. 2.1. II.). Additionally, significant elevation was observed in
309	the PS single positive PLT population (% PS positive PLTs±SEM: 13.17±2.05 vs.
310	2.66±0.52, p value <0.0001; and vs. 2.36±0.29, p value 0.0002, Fig. 2.1. I) but not in
311	the percentage of CD62p single positive PLTs (% CD62p positive PLTs±SEM:
312	19.40±1.83 vs. 13.53±1.90, p value 0.1011, Fig. 2.1. III).
313	Next, we sought to investigate the ability of IgG fractions from patients with
314	severe COVID-19 to cause increased clot formation. PLTs from healthy individuals
315	were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to
315 316	were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered
315 316 317	were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered microfluidic channels at a shear rate of 1500 s ⁻¹ (60 dyne). As shown in Fig. 3 A, IgG
315 316 317 318	were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered microfluidic channels at a shear rate of 1500 s ⁻¹ (60 dyne). As shown in Fig. 3 A, IgG from severe COVID-19 patients caused increased clot formation. Overall, significantly
315316317318319	 were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered microfluidic channels at a shear rate of 1500 s⁻¹ (60 dyne). As shown in Fig. 3 A, IgG from severe COVID-19 patients caused increased clot formation. Overall, significantly higher surface area coverage by thrombus (SAC) was observed in the presence of
 315 316 317 318 319 320 	 were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered microfluidic channels at a shear rate of 1500 s⁻¹ (60 dyne). As shown in Fig. 3 A, IgG from severe COVID-19 patients caused increased clot formation. Overall, significantly higher surface area coverage by thrombus (SAC) was observed in the presence of ICU COVID-19 IgGs compared to ICU controls and HCs (mean % SAC±SEM:
 315 316 317 318 319 320 321 	 were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered microfluidic channels at a shear rate of 1500 s⁻¹ (60 dyne). As shown in Fig. 3 A, IgG from severe COVID-19 patients caused increased clot formation. Overall, significantly higher surface area coverage by thrombus (SAC) was observed in the presence of ICU COVID-19 IgGs compared to ICU controls and HCs (mean % SAC±SEM: 13.95%±1.55 vs. 2.86±1.10, p value 0.0070; and vs. 2.70±0.83, p value 0.0002,
 315 316 317 318 319 320 321 322 	 were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered microfluidic channels at a shear rate of 1500 s⁻¹ (60 dyne). As shown in Fig. 3 A, IgG from severe COVID-19 patients caused increased clot formation. Overall, significantly higher surface area coverage by thrombus (SAC) was observed in the presence of ICU COVID-19 IgGs compared to ICU controls and HCs (mean % SAC±SEM: 13.95%±1.55 vs. 2.86±1.10, p value 0.0070; and vs. 2.70±0.83, p value 0.0002, respectively, Fig. 3 B). Together with the increased percentage of procoagulant PLTs
 315 316 317 318 319 320 321 322 323 	 were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered microfluidic channels at a shear rate of 1500 s⁻¹ (60 dyne). As shown in Fig. 3 A, IgG from severe COVID-19 patients caused increased clot formation. Overall, significantly higher surface area coverage by thrombus (SAC) was observed in the presence of ICU COVID-19 IgGs compared to ICU controls and HCs (mean % SAC±SEM: 13.95%±1.55 vs. 2.86±1.10, p value 0.0070; and vs. 2.70±0.83, p value 0.0002, respectively, Fig. 3 B). Together with the increased percentage of procoagulant PLTs (CD62p/PS positive) in response to ICU COVID-19 IgGs, these findings might
 315 316 317 318 319 320 321 322 323 324 	 were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to autologous whole blood samples and finally perfused throw collagen covered microfluidic channels at a shear rate of 1500 s⁻¹ (60 dyne). As shown in Fig. 3 A, IgG from severe COVID-19 patients caused increased clot formation. Overall, significantly higher surface area coverage by thrombus (SAC) was observed in the presence of ICU COVID-19 IgGs compared to ICU controls and HCs (mean % SAC±SEM: 13.95%±1.55 vs. 2.86±1.10, p value 0.0070; and vs. 2.70±0.83, p value 0.0002, respectively, Fig. 3 B). Together with the increased percentage of procoagulant PLTs (CD62p/PS positive) in response to ICU COVID-19 IgGs, these findings might provide a potential explanation for the increased thromboembolic events in severely

326 ICU COVID-19 IgGs cause procoagulant PLTs via crosslinking FcyRIIA

327 To further determine the underlying mechanistic pathways leading to ICU COVID-19 IgG induced formation of procoagulant PLTs, we next considered a potential ligation 328 329 of FcyRIIA by patients, sera/IgGs. For this purpose, wPLTs were pretreated with the 330 moAb IV.3. This FcyRIIA blockade resulted in marked inhibition of the antibody-331 induced $\Delta \psi$ depolarization (FI in % $\Delta \psi$ depolarization±SEM: 5.51±0.94 vs. 332 1.18±0.08, p value 0.0020, Fig. 4.1. A) as well as significant reduction of caspase 333 activation (Ratio of cleaved caspase 3/procaspase 3±SEM: 4.70±1.16 vs. 1.33±0.29, 334 p value 0.0286, Fig. 4.1. B+C). Intriguingly, the blockade of FcyRIIA almost abolished 335 the changes in PLTs' FSC and SSC properties (Fig. 4.2. A+C), and markedly 336 reduced CD62p/PS double positive PLT population compared to isotype-control (% 337 CD62p/PS positive PLTs±SEM: 48.91±3.05 vs. 12.88±1.65, p value 0.0078, Fig. 4.2. 338 II). 339 Next, we analyzed the impact of FcyRIIA blockade on antibody-mediated clot 340 formation. Pretreatment of PLTs with moAb IV.3 prior to ICU COVID-19 IgG 341 incubation resulted in significant reduction of clot formation compared to isotypecontrol (mean % SAC±SEM: 16.49±1.02 vs. 5.84±1.93, respectively, p value 0.0090, 342 343 Fig. 5 A+B). These results indicate that ICU COVID-19 IgG antibodies that are present in a subgroup of severe ICU COVID-19 patients have the capability to induce 344 345 formation of procoagulant PLTs with increased clotting ability via crosslinking 346 FcyRIIA.

347 Calcium is pivotal for the generation of ICU COVID-19-IgG induced
 348 procoagulant PLTs

349	Following the detection of an ICU COVID-19 IgG-induced procoagulant PLT
350	phenotype, we sought to investigate the underlying intracellular molecular
351	mechanisms. The contribution of calcium was analyzed by the depletion of extra- and
352	intracellular calcium contents via EGTA and BAPTA, respectively. Extracellular
353	calcium depletion caused significant inhibition of $\Delta\psi$ depolarization (FI in % $\Delta\psi$
354	depolarization±SEM: 3.08±0.18 vs. 1.94±0.20, p value 0.0079, Fig. 6.1. A) as well as
355	marked reduction of caspase 3 cleavage (Ratio of cleaved caspase 3/procaspase
356	3±SEM: 4.14±0.65 vs. 1.50±0.20, p value 0.0079, Fig. 6.1. B+C). Moreover,
357	depletion of extracellular calcium significantly inhibited ICU COVID-19 IgG induced
358	alterations of wPLTs´ morphology (Fig. 6.2. A-D) as well as the generation of
359	CD62p/PS positive PLTs (% CD62p/PS positive PLTs±SEM: 32.89±2.77 vs.
360	6.42±1.21, p value 0.0039, Fig. 6.2. II).
361	Similar effects were observed as depleting intracellular calcium stores. BAPTA
362	treatment resulted in significant inhibition of ICU COVID-19 IgG-induced $\Delta\psi$
363	depolarization (FI in % $\Delta \psi$ depolarization±SEM: 4.46±0.73 vs. 0.99±0.09, p value
364	0.0039, Fig. 7.1. A) and caspase 3 cleavage (Ratio of cleaved caspase 3/procaspase
365	3±SEM: 3.50±0.98 vs. 0.43±0.06, p value 0.0286, respectively, Fig. 7.1. B+C). In
366	addition, BAPTA pretreatment of wPLTs resulted in marked prevention of ICU
367	COVID-19 IgG-induced changes in FSC and SSC (Figure 7.2. A-D as well as
368	significant reduction of CD62p/PS positive PLTs (% CD62p/PS positive PLTs:
369	29.58±3.36 vs. 1.74±0.39, p value 0.0020, Fig. 7.2. II).
370	Activation of cAMP protects against ICU COVID-19 IgG induced procoagulant

- 371 **PLTs**
- The interplay between the signalling pathways of the intracellular second
- 373 messengers, cAMP and calcium, has been shown to have an important role in

374 numerous essential physiological processes during PLT activation and apoptosis (16, 375 17). Therefore, we investigated the role of cAMP on COVID-19 antibody-induced formation of procoagulant PLTs. Forskolin, an activator of intracellular ADC that 376 377 elevates intracellular levels of cAMP, was recently reported to inhibit the formation of apoptotic PLTs in immune thrombocytopenia (18). The pretreatment of PLTs with 378 379 Forskolin led to significant reduction of ICU COVID-19 IgG-induced Δψ depolarization 380 (FI in % Δψ depolarization±SEM:5.10±0.70 vs. 1.43±0.17, p value 0.0079, Fig. 8.1. 381 A) and caspase 3 cleavage (Ratio of cleaved caspase 3/procaspase 3±SEM: 3.74±1.14 vs. 1.01±0.14, p value 0.0313, respectively, Fig. 8.1. B+C). In addition, 382 383 Forskolin pretreatment of wPLTs led to reduction of ICU COVID-19 IgG-induced 384 changes in FSC and SSC properties (Fig. 8.2. A-D) as well as to a significant inhibition of procoagulant PLT generation (% CD62p/PS positive PLTs±SEM: 385 386 35.29±1.58 vs. 12.26±2.74, p value 0.0313, Fig. 8.2. II). These findings indicate that 387 the elevation of intracellular cAMP prevents ICU COVID-19 IgG-induced formation of 388 procoagulant PLTs. 389 More importantly and of high clinical interest, similar protective effect was observed with lloprost, an already approved cAMP inducer (19). In fact, lloprost 390 391 pretreatment of wPLTs led to marked reductions of ICU COVID-19 IgG-induced $\Delta \psi$ 392 depolarization (FI of % Δψ depolarization±SEM: 4.66±0.57 vs. 1.77 ±0.32, p value 393 0.0078, Fig. 9.1. A), and cleavage of caspase 3 (Ratio of cleaved caspase 394 3/procaspase 3±SEM: 4.69±1.45 vs. 2.0348±0.38, p value 0.0156, respectively, Fig. 395 9.1. B+C). In addition, lloprost pretreatment led to a significant reduction of changes 396 in PLT morphology (Fig. 9.2. A-D) as well as in the number of procoagulant

397 CD62p/PS positive PLTs (% CD62p/PS positive PLTs±SEM: 41.36±3.60 vs.

398 22.22±3.92, p value 0.0156, Fig. 9.2. II). Noteworthy, no significant changes were

- 399 observed in the number of CD62p single positive PLTs (% CD62p positive
- 400 PLTs±SEM: 24.48±2.2 vs. 26.51±3.94, p value 0.6875).
- 401 Based on these findings we were interested whether lloprost might affect the
- 402 ability to form blood clots. Pretreatment of PLTs with lloprost showed a marked
- 403 reduction in ICU COVID-19 IgG-induced clot formation compared to vehicle (mean %
- 404 SAC±SEM: 14.63±2.31 vs. 3.85±0.95, respectively, p value 0.0079, Fig. 10. A+B).
- 405 These findings provide the first evidence for a potential therapeutic use of lloprost in
- 406 the treatment of the antibody-induced coagulopathy that is observed in COVID-19
- 407 disease.

408 **Discussion**

Our study showed that IgGs from patients with severe COVID-19 are able to induce
procoagulant PLTs with increased potential for clot formation via crosslinking FcγRIIA
in a calcium depending manner. Most importantly, we showed that cAMP activation
by an approved drug, namely lloprost, can sufficiently inhibit the initiation of
procoagulant PLTs and the subsequent increased clot formation. These data may
have tremendous clinical implications.

415 Meanwhile, it is well established that COVID-19 infection is associated with 416 systemic prothrombotic state and increased incidence of thromboembolic 417 complications (20). However, the pre-sequelae events leading to the coagulopathy 418 observed in COVID-19 still remains elusive. Data from our study demonstrate the 419 presence of PLT-reactive IgG antibodies that harbour the ability to induce marked 420 changes in PLTs in terms of increased $\Delta \psi$ depolarization, PS externalization and P-421 selectin expression, which are characteristic for procoagulant PLTs. A novel finding, 422 and potentially of high clinical interest, is that antibody-mediated formation of 423 procoagulant PLTs was associated with the clinical course as these changes 424 progressively increased as patients needed ventilation and peaked between day 3 425 and 7 on ICU. Probably, the kinetic of these markers might have predictive value to 426 monitor COVID-19-induced coagulopathy. In fact, PS externalization was recently 427 found to be a predictive biomarker for thromboembolic complications related to 428 cardiovascular therapeutic devices (21). In contrast to PS, conventional markers of 429 PLT activation were declared in this study to fail the detection of early activation 430 events leading to thrombosis.

431 The alterations in PLTs that were observed in our study after incubation with 432 sera from patients with severe COVID-19 infection, such as $\Delta \psi$ disruption, caspase 3

433 cleavage and PS externalization, could be found in apoptotic as well as procoagulant 434 PLTs. The involvement of PLT apoptosis to promote prothrombotic conditions has 435 been controversially discussed. In fact, recent data suggests that apoptotic PLTs are 436 unable to promote prothrombotic conditions (10). However, a clear dissection of the molecular events leading to prothrombotic PLTs is challenging since activation of the 437 438 apoptosis caspase pathway has been described in the late phase of agonist-induced 439 PLT activation as well as in PLTs from patients with chronic kidney disease (22, 23), 440 which are prone to thromboembolic events. Our findings showed that antibody-441 mediated $\Delta \psi$ disruption and caspase cleavage is associated with the induction of a 442 CD62p/PS positive PLT population suggesting that IgG antibodies in COVID-19 induce procoagulant rather than apoptotic PLTs. In fact, activated PLTs were shown 443 444 elsewhere to be predominant in COVID-19 patients (6). In particular, CD62p positive 445 PLTs were suggested to be involved in thrombosis in COVID-19 via the interaction 446 with neutrophil granulocytes leading to NET formation and increased interaction with 447 the inflamed vessel wall. Our data showed that COVID-19 IgG-antibodies trigger a 448 PLT population with procoagulant potential. An important finding that was reinforced 449 by data from an ex vivo microfluidic circulation system which revealed an increased clot formation in the presence of COVID-19 IgG-antibodies. 450

451 Motivated by these novel functional data, we thought to dissect the exact 452 mechanistic pathways involved in the COVID-19 IgG-induced procoagulant status. 453 We found that ICU COVID-19 IgG-mediated changes in wPLTs involves the ligation 454 of the immune receptor FcyRIIA. The blockade of FcyRIIA significantly inhibits ICU 455 COVID-19 IgG-induced changes in $\Delta \psi$ depolarization as well as cleavage of caspase 456 3. Most importantly, FcyRIIA blockade reduced procoagulant CD62p/PS positive 457 PLTs and subsequently inhibited COVID-19 antibody-induced ex vivo clot formation. 458 While this findings are novel for COVID-19-associated coagulopathy, the correlation

between FcyRIIA ligation and increased risk for thromboembolic events is well 459 460 established for heparin-induced thrombocytopenia (HIT) (24). Interestingly, the IgG antibody formation peaks in HIT within 5-10 day after exposure to heparin and is 461 462 associated with PLT consumption and increased risk for thrombosis (25). Similarly, in our study the ability of ICU COVID-19 sera to induce procoagulant PLTs was most 463 464 pronounced between day 3 and 7. Of note, antibody-induced alterations in PLT 465 markers were accompanied by enhanced levels of IgG antibodies against the Spike S epitope of SARS-CoV-2. These findings might suggest a transient onset of 466 467 misdirected autoimmune mechanisms that result in the emergence of PLT-reactive 468 antibodies leading to a prothrombotic status in severe COVID-19 infection. 469 Calcium is involved in many biological mechanistic pathways in PLTs (16). In 470 response to PLT agonists, calcium is released from the PLT internal stores which is 471 followed by amplifying second wave extracellular calcium influx via store (SOCE) and 472 receptor operated calcium entry (ROCE), respectively (26). The role of calcium 473 signalling in ITAM (immunoreceptor tyrosine-based activation motif) coupled GPVI 474 and (hem)ITAM coupled CLEC-2 receptor signalling has been well established in the 475 last few years (27). Additionally, FcyRIIA ligation has been shown to induce calcium 476 mobilization via ITAM signalling prior to platelet aggregation(28). In our study, the 477 depletion of calcium in the extracellular compartment inhibited ICU COVID-19 IgG-478 induced procoagulant changes. This finding indicates that alterations in SOCE or 479 ROCE might be involved in the antibody-mediated generation of procoagulant PLTs 480 in COVID-19. In fact, the regulative role of SOCE for procoagulant PS externalization 481 has been previously reported, as SOCE channel inhibition resulted in reduced PS 482 externalization in human erythroleukemia cells (29). In addition, reduced PS 483 externalization and decreased clot formation was observed in chimeric mice that 484 express mutated impaired SOCE calcium channel Orai1 R93W on the PLT surface,

485 indicating that SOCE is a major inductor of PLT PS externalization and procoagulant 486 PLT formation (30). A potential role of ITAM-regulated signalling leading to 487 procoagulant PLTs has been also suggested. Calcium depletion inhibited GP VI 488 induced formation of procoagulant PLTs (31). In this study, the authors proposed that 489 distinct signalling cascades, most likely tyrosine and extracellular calcium dependent, 490 could be involved in the formation of procoagulant PLTs. Our findings emphasize the 491 role of extracellular calcium in FcyRIIA (ITAM) mediated procoagulant PLT formation. 492 Another possible explanation for these finding could be the loss of distinct calciumdependent conformational properties of PLT epitopes that are targeted by COVID-19 493 494 IgG antibodies. Dimeric PLT GP IIb/IIIa, the receptor for fibrinogen and well known immunogenic epitopes of PLT-reactive autoantibodies in immune thrombocytopenia 495 496 (ITP), has been well characterized to be structurally dependent on extracellular 497 calcium levels (32). Although this might be currently too speculative, the depletion of 498 extracellular calcium might have inhibited antibody binding to such conformation-499 sensitive epitopes on GP IIb/IIIa. ICU COVID-19 IgG-induced PLT alterations were 500 dependent on extracellular as well as intracellular calcium levels. Since PLT 501 apoptosis has been described to be independent of calcium (33), our finding 502 indicates that COVID-19 IgGs trigger FcyRIIA -mediated events that result in 503 procoagulant PLT formation in a calcium-dependent manner. In fact, similar findings 504 were reported by recently showing that actin-mediated PLT shape change and 505 phosphoinositide 3-kinase activity in response to FcyRIIA ligation in dependent on 506 intracellular calcium (28). The absence of ICU COVID-19 IgG-mediated PLT changes 507 could be also due to inactivation of calcium dependent cysteine protease calpain that 508 is crucial for the conformational changes in GP IIb/IIIa (34, 35). Another possible 509 explanation could be the inactivation of calcium dependent TMEM16F that bears 510 essential properties for membrane phospholipid scrambling and microparticle

511 generation (10). Future studies could explore the exact mechanisms by which 512 calcium contributes to procoagulant PLT formation in COVID-19. 513 COVID-19 antibody-induced procoagulant PLTs were significantly inhibited by 514 the use of inducers of adenylate cyclase (ADC) that are well known to cause 515 increased cAMP levels in PLTs (36). The protective effect of cAMP was further 516 demonstrated, as lloprost, an already approved prostacyclin derivate and ADC, efficiently prevented the formation of procoagulant PLTs in response to COVID-19 517 518 antibodies. Finally and of high clinical importance, lloprost pretreatment of PLTs markedly reduced COVID-19 IgG-induced clot formation on collagen suggesting that 519 520 cAMP inducers may have potential to prevent life threatening thromboembolic events in COVID-19 antibody-mediated coagulopathy. Another minor finding from our 521 522 microfluidic system was that lloprost, although significantly inhibited antibody-523 mediated thrombus formation, did not affect the CD62p-single positive population. 524 Since Iloprost prevented clot formation, this finding might indicate that PS rather than 525 CD62p exposure on the PLT surface is pivotal to trigger the onset of thromboembolic 526 events. 527 Our study is subjected to some limitations. First, as an observational, 528 monocentric study, we cannot conclude that the reported associations between IgG

the thrombosis or specific for the disease. Second, we cannot exclude the possibility of remaining residual confounding or unmeasured potential confounders in our mechanistic studies. Third, the low number of patients does not enable a final and robust statistical analysis to assess clinical outcomes in patients with increased

antibodies and changes in activation/apoptosis markers in COVID-19 are causal for

534 procoagulant PLTs. Nevertheless, data presented in this study may provide a

535 background for future studies to dissect mechanisms related to PLT activation that

are involved in the progression of COVID-19.

529

- Taken together, our study shows that IgG antibodies from patients with severe
 COVID-19 are able to stimulate FcγRIIA leading to the induction of procoagulant
 PLTs with an increased ability of clot formation. These processes are dependent on
 calcium and can be efficiently inhibited by cAMP inducers suggesting that ADC might
 represent a potentially promising target to prevent thromboembolic complications in
 COVID-19 disease.
- 545
- 546

547

548 Author contributions

- 549 J.Z., K.A., T.B. and P.R. designed the study. P.R. and H.H. were responsible for the
- 550 treatment of the patients. K.A. and H.H. collected and analyzed the clinical data. J.Z.,
- 551 K.A., H.J., L.P., A.S. and A.W. performed the experiments. J.Z., K.A., H.J., L.P., A.S.
- and A.W. collected the data. J.Z., K.A., H.J., L.P., A.S., A.W., V.M., P.R. and T.B.
- analyzed the data, interpreted the results and wrote the manuscript. All authors read
- and approved the manuscript.

555

556 **Conflict of interest**

- 557 The authors have no conflict of Interests.
- 558

559 Acknowledgements

- 560 This work was supported by grants from the "Ministerium für Wissenschaft,
- 561 Forschung und Kunst Baden-Württemberg" to J.Z. and T.B. and from the Herzstiftung
- to T.B. (BA5158/4 and TSG-Study) and TÜFF-Gleichstellungsförderung to K.A.
- 563 (2563-0-0). We thank Karoline Weich for her excellent technical support. The authors
- thank Susanne Staub for editing the article as native English speaker.

565

- 567
- 568
- 569
- 570

571 Figure legends

572 Fig. 1-ICU COVID-19 patient serum induced effects on PLTs during disease.

573 (A+B) ICU COVID-19 (n=26) or ICU non-COVID-19 control (n=5) patient serum 574 induced changes in $\Delta \psi$ as well as PS externalization in wPLTs were analyzed by FC. 575 (C+D) Sera of 4 ICU COVID-19 patients were collected for up to 14 days during 576 hospitalization and analyzed for their ability to induce changes in $\Delta \psi$ as well as PS 577 externalization in wPLTs via FC. (E) Representative WB image of detected cleaved 578 caspase 3 (cleaved-) and procaspase 3 (pro-) levels in wPLTs that were incubated 579 with follow up sera of one ICU COVID-19 patient (indicated in C+D). (F) 580 Densitometric analysis of cleaved caspase 3/procaspase 3 ratios in wPLTs that were 581 incubated with follow up sera of ICU COVID-19 patients (n=4, [indicated in C+D]) 582 normalized to control. α-Tubulin served as loading control. Data are presented as 583 mean±SEM of the measured fold increase compared to control. ns, not significant; 584 *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of patient sera tested is 585 reported in each graph. Dot lines in (A+B) represent the calculated cutoffs 586 determined testing sera from healthy donors as mean of fold increase (FI)+2xSEM. 587 HC, healthy control; $\Delta \psi$, inner mitochondrial transmembrane potential; N, number of 588 HCs or patients; PS, phosphatidylserine.

589 Fig. 2-ICU COVID-19 IgGs induce procoagulant PLTs and increased clot

590 formation.

591 Fig. 2.1. (A+C) Representative FC plots of wPLTs' FSC vs. SSC properties after HC

592 or ICU COVID-19 IgG incubation. (B+D) Following HC or ICU COVID-19 IgG

593 incubation, CD42a positive gated wPLTs were analyzed for PS externalization and

594 expression of CD62p via Annexin V-FITC and CD62p-APC antibody staining,

respectively. Fig. 2.1. (I-IV) represent quantitative gate distribution of CD42a positive
events as indicated in Fig. 2.1. (B+D). Data are shown as percentage±SEM of
Annexin V-FITC and or CD62p-APC positive labeled wPLTs after incubation with HC
(n=8), ICU non-COVID-19 (n=5) or ICU COVID-19 IgG (n=10). ns, not significant;
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients and healthy
donors tested is reported in each graph. HC, healthy control; N, number of HCs or
patients; PS, phosphatidylserine.

Fig. 3-ICU COVID-19 IgG cause increased clot formation on collagen.

603 (A) PRP from healthy individuals with the blood group O was incubated with HC 604 (n=6), ICU non-COVID-19 control (n=3) or ICU COVID-19 IgG (n=10), labelled with FITC conjugated calcein and perfused through microfluidic channels at a shear rate 605 606 of 1500⁻¹ (60 dyne) for 5 min after reconstitution into autologous whole blood. Images 607 were aquired at x20 magnification in the fluorescent (upper panel) as well as in the BF channel (lower panel). Scale bar 50µm. (B) Mean percentage of surface area 608 609 covered (mean % SAC)±SEM by thrombus in the presence of HC (n=6), ICU non-610 COVID-19control (n=3) and ICU COVID-19 (n=10) IgG after 5 min perfusion time. ns, not significant; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of 611 612 patients and healthy donors tested is reported in each graph. HC, healthy control; N, 613 number of HCs or patients.

Fig. 4-ICU COVID-19 IgG induced formation of procoagulant PLTs is FcγRIIA dependent.

Fig. 4.1. (A) ICU COVID-19 patient serum (n=10) induced changes of $\Delta \psi$ in wPLTs were analyzed in the presence or absence of moAb IV.3 via FC. Data are presented as mean±SEM of the measured fold increase compared to control. (**B+C**)

619 Representative WB image of detected cleaved caspase 3 (cleaved-) and procaspase 620 3 (pro-) levels in wPLTs that were incubated with ICU COVID-19 IgG (n=4) in the presence or absence of moAb IV.3. α-Tubulin served as loading control. (C) 621 622 Densitometric analysis of cleaved caspase 3/procaspase 3 ratios from immunoblots as indicated in (B, n=4) normalized to control. Fig. 4.2. (A+C) Representative FC 623 624 plots of wPLTs' FSC vs. SSC after ICU COVID-19 IgG incubation in IV.3 pretreated 625 wPLTs. (**B+D**) Gate distribution of CD42a positive PS (Annexin V-FITC) externalizing 626 and CD62p (CD62p-APC) expressing wPLTs after ICU COVID-19 IgG incubation in isotype control or IV.3 pretreated wPLTs. Fig. 4.2. (I-IV) shows quantitative gate 627 628 distributions of wPLTs with or without IV.3 pretreatment, after ICU COVID-19 IgG incubation as shown in Fig. 4.2. (B+D). Data are presented as percentage±SEM of 629 630 Annexin V-FITC and or CD62p-APC positive labeled wPLTs after incubation with HC 631 (n=3) or ICU COVID-19 IgG (n=8) in the presence or absence of moAb IV.3. ns, not 632 significant; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients 633 and healthy donors tested is reported in each graph. HC, healthy control; N, number 634 of HCs or patients; PS, phosphatidylserine.

Fig. 5-FcγRIIA inhibition prevents ICU COVID-19 IgG induced increased clot formation.

(A) PRP from healthy individuals with the blood group O was incubated with HC (n=2) or ICU COVID-19 IgG (n=3 patients) in the presence of moAb IV.3 or isotype control (moAb) and perfused through microfluidic channels at a shear rate of 1500^{-1} (60 dyne) for 5 min. Images were aquired at x20 magnification in fluorescent (upper panel) as well as in the BF channel (lower panel). Scale bar 50µm. (**B**) mean % SAC±SEM induced by HC (n=2) or ICU COVID-19 IgG (n=3) in the presence or absence of moAb IV.3 or isotype control (moAb). ns, not significant; *p<0.05,

⁶⁴⁴ **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients and healthy donors
⁶⁴⁵ tested is reported in each graph. moAb, monoclonal isotype control; HC, healthy
⁶⁴⁶ control; N, number of HCs or patients

647 Fig. 6-ICU COVID-19 IgG induced formation of procoagulant PLTs is dependent

- 648 on extracellular calcium.
- **Fig. 6.1. (A)** FC assessment of ICU COVID-19 IgG (n=5) induced changes of $\Delta \psi$ in
- 650 wPLTs that were pretreated with EGTA (1 mM) or vehicle. Data are presented as
- 651 mean±SEM of the measured fold increase compared to control. (**B+C**)
- 652 Representative WB image of detected cleaved caspase 3 (cleaved-) and procaspase
- 653 3 (pro-) levels in EGTA (1 mM) vehicle pretreated wPLTs that were incubated with
- 654 ICU COVID-19 IgG (n=6), respectively. α-Tubulin served as loading control. (**C**)
- 655 Densitometric analysis of immunoblots indicated in (**B**) for cleaved caspase
- 656 3/procaspase 3 ratios from WB data as indicated in (**B**, [n=5]) normalized to control.
- 657 Fig. 6.2. (A+C) Representative FC plots of wPLTs' FSC vs. SSC after ICU COVID-
- 19 IgG incubation in EGTA (1mM) or vehicle pretreated wPLTs. (**B+D**) Gate
- distribution of CD42a positive PS (Annexin V-FITC) externalizing and CD62p
- 660 (CD62p-APC) expressing wPLTs after ICU COVID-19 IgG incubation in EGTA (1mM)
- or vehicle pretreated wPLTs. Fig. 6.2. (B+D) Gate distribution of CD42a positive PS
- 662 (Lactadherin-FITC) externalizing and CD62p (CD62p-APC) expressing wPLTs after
- 663 ICU COVID-19 IgG incubation in EGTA (1 mM) or vehicle containing wPLTs. Fig.
- 664 **6.2.** (I-IV) shows quantitative gate distribution of wPLTs after incubation with ICU
- 665 COVID-19 IgG. Data are presented as percentage±SEM of Lactadherin-FITC or
- 666 CD62p-APC positive labeled wPLTs after incubation with HC (n=3) or ICU COVID-19
- IgG (n=9) in vehicle or EGTA (1 mM) pretreated wPLTs. ns, not significant; *p<0.05,
- ⁶⁶⁸ **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients and healthy donors

tested is reported in each graph. HC, healthy control; N, number of HCs or patients;

670 PS, phosphatidylserine.

671 Fig. 7-Depletion of intracellular calcium abrogates ICU COVID-19 IgG induced

- 672 procoagulant PLT formation.
- 673 Fig. 7.1 (A) ICU COVID-19 IgG (n=9) induced changes of Δψ in wPLTs were
- analyzed in the presence or absence of the intracellular calcium chelator BAPTA (20
- 675 μM). (B) Representative WB image of cleaved caspase 3 (cleaved-) and procaspase
- 676 3 (pro-) were detected with anti-caspase 3 antibody in wPLTs that were incubated
- 677 with ICU COVID-19 IgG in BAPTA (20 μM) or vehicle pretreated wPLTs. α.Tubulin
- 678 served as loading control. (C) Densitometric analysis of cleaved caspase
- 679 3/procaspase 3 ratios from immunoblots (indicated in **B**, [n=4]) normalized to control.
- 680 Fig. 7.2. (A+C) FC plots of wPLTs' FSC and. SSC after ICU COVID-19 IgG
- 681 incubation in vehicle or BAPTA (20 μM) preloaded wPLTs. (B+D) FC plots of CD42a
- 682 positive gated wPLTs that were incubated with ICU COVID-19 IgG in vehicle or in
- 683 BAPTA (20 μM) preloaded wPLTs. Fig. 7.2.(I-IV) quantitative gate distribution of
- 684 CD42a positive wPLTs based on the gate settings shown in **Fig. 7.2.** (**B+D**). Data are
- shown as percentage±SEM of Lactadherin-FITC and or CD62p-APC positive labeled
- 686 wPLTs after HC (n=3) or ICU COVID-19 IgG (n=10) incubation in normal or BAPTA
- 687 (20 μM) preloaded wPLTs. Ns,not significant; *p<0.05, **p<0.01, ***p<0.001 and
- ⁶⁸⁸ ****p<0.0001. The number of patients and healthy donors tested is reported in each
- graph. HC, healthy control; N, number of HCs or patients, PS; phosphatidylserine.

690 Fig. 8-Forskolin protects ICU COVID-19 IgG induced procoagulant PLT

691 formation.

692 **Fig. 8.1.** (A) FC analysis of ICU COVID-19 lgG (n=5 patients) induced changes in $\Delta \psi$ 693 of wPLTs, that were pretreated with vehicle or the ADC inductor Forskolin (2.25 µM) 694 for 30 min at 37°C. Data are presented as mean±SEM of the measured fold increase 695 compared to control. (B) Representative WB image of cleaved caspase 3 (cleaved-) 696 and procaspase 3 (pro-) levels detected in wPLTs that were incubated with ICU 697 COVID-19 IgG in vehicle or Forskolin (2.25 μM) pretreated wPLTs. α-Tubulin served 698 as loading control. (C) Densitometric assessed ratios of cleaved caspase 699 3/procaspase 3 (as indicated in B [n=6]) normalized to control. Fig. 8.2. (A+C) FC 700 plots of wPLTs' FSC vs. SSC after ICU COVID-19 IgG incubation in vehicle or 701 Forskolin (2.25 µM) pretreted wPLTs. (**B+D**) Gate distribution of CD42a positive 702 wPLTs that were incubated with ICU COVID-19 IgG vehicle or Forskolin (2.25 µM) 703 pretreated wPLTs. Fig. 8.2. (I-IV) Quantitative distribution of CD42a positive wPLTs 704 based on the gate settings shown in Fig. 8.2. (B+D). Data are shown as percentage 705 ±SEM of Annexin V-FITC and or CD62p-APC positive labeled wPLTs that were 706 incubated with IgGs from HC (n=3) or ICU COVID-19 IgG (n=6) in vehicle or 707 Forskolin (2.25 µM) pretreated wPLTs. ns, not significant; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients and healthy donors tested is 708 709 reported in each graph. HC, healthy control; N, number of HCs or patients; PS, 710 phosphatidylserine.

711

Fig. 9-cAMP elevation via lloprost prevents ICU COVID-19 lgG induced
procoagulant PLTs.

Fig. 9.1. (A) Changes in Δψ depolarization induced by ICU COVID-19 IgG (n=8
patients) were analyzed in vehicle or Iloprost (20 nM) pretreated wPLTs via FC. Data

716 are presented as mean±SEM of the measured fold increase compared to control. (B) 717 Representative WB image of detected caspase 3 (cleaved-) and procaspase 3 (pro-) 718 levels in wPLTs that were pretreated with vehicle or lloprost (20 nM) prior to ICU 719 COVID-19 IgG incubation. α-Tubulin served as loading control. (C) Densitometric 720 analysis of cleaved caspase 3/procaspase 3 ratios from the WB data (indicated in **B**, 721 [n=7]) normalized to control. Fig. 9.2. (A+C) FC detected changes in wPLTs' FSC vs. 722 SSC properties after ICU COVID-19 IgG incubation in vehicle or Iloprost (20 nM) 723 pretreated wPLTs. Fig. 9.2. (B+D) (E+G) Gate distribution of CD42a positive vehicle 724 or lloprost (20 nM) pretreated wPLTs that were incubated with ICU COVID-19 lgG. 725 Fig. 9.2. (I-IV) Quantitative distribution of the CD42a positive wPLT population based 726 on the gate settings shown in **Fig. 9.2.** (**B+D**). Data are shown as percentage±SEM 727 of Annexin V-FITC and or CD62p-APC positive labeled wPLTs that were incubated 728 with HC (n=3) or ICU COVID-19 IgG (n=6) in vehicle or Iloprost (20 nM) pretreated 729 wPLTs. ns, not significant; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The 730 number of patients and healthy donors tested is reported in each graph. HC, healthy 731 control; N, number of HCs or patients; PS, phosphatidylserine.

732 Fig. 10-lloprost inhibits ICU COVID-19 IgG induced increased clot formation.

733 (A) PRP from healthy individuals with the blood group O was incubated with HC 734 (n=3) or ICU COVID-19 IgG (n=5) in the presence of vehicle or Iloprost (20 nM). After 735 resonstituion into autologous whole blood, samples were perfused through 736 microfluidic channels at a shear rate of 1500⁻¹ (60 dyne) for 5 min. Pictures were aquired at x20 magnification in fluorescent (upper panel) as well as in the BF channel 737 738 (lower panel). Scale bar 50µm. (B) Mean % SAC±SEM induced by HC (n=3) or ICU 739 COVID-19 IgG (n=5) in the presence of vehicle or lloprost (20 nM). ns,not significant; 740 *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients and healthy

All rights reserved. No reuse allowed without permission.

- donors tested is reported in each graph. HC, healthy control; N, number of HCs or
- 742 patients; PS, phosphatidylserine.

743

744

745 **References:**

746

747 1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of 748 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 749 2020;395(10229):1054-62. 750 2. Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID-19. Am J Hematol. 751 2020;95(12):1578-89. 752 Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit 3. 753 Care Med. 2020;48(9):1358-64. 754 Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of 4. 755 renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167-73. 756 757 Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pao CRR, et al. Platelet 5. 758 activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients

759 with severe COVID-19. Blood. 2020;136(11):1330-41.

7606.Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene761expression and function in patients with COVID-19. Blood. 2020;136(11):1317-29.

- 762 7. de Witt SM, Verdoold R, Cosemans JM, Heemskerk JW. Insights into platelet-based control of
 763 coagulation. Thromb Res. 2014;133 Suppl 2:S139-48.
- 7648.Swieringa F, Spronk HMH, Heemskerk JWM, van der Meijden PEJ. Integrating platelet and765coagulation activation in fibrin clot formation. Res Pract Thromb Haemost. 2018;2(3):450-60.

Agbani EO, Poole AW. Procoagulant platelets: generation, function, and therapeutic targeting
 in thrombosis. Blood. 2017;130(20):2171-9.

Reddy EC, Rand ML. Procoagulant Phosphatidylserine-Exposing Platelets in vitro and in vivo.
 Front Cardiovasc Med. 2020;7:15.

Hua VM, Chen VM. Procoagulant platelets and the pathways leading to cell death. Semin
Thromb Hemost. 2015;41(4):405-12.

Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing
 heparin-associated thrombocytopenia. Thromb Haemost. 1991;66(6):734-6.

Marini I, Zlamal J, Faul C, Holzer U, Hammer S, Pelzl L, et al. Autoantibody-mediated
 desialylation impairs human thrombopoiesis and platelet life span. Haematologica. 2019.

Mangin PH, Gardiner EE, Nesbitt WS, Kerrigan SW, Korin N, Lam WA, et al. In vitro flow based
systems to study platelet function and thrombus formation: Recommendations for standardization:
Communication from the SSC on Biorheology of the ISTH. J Thromb Haemost. 2020;18(3):748-52.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

Mammadova-Bach E, Nagy M, Heemskerk JWM, Nieswandt B, Braun A. Store-operated
 calcium entry in thrombosis and thrombo-inflammation. Cell Calcium. 2019;77:39-48.

17. Nagy Z, Smolenski A. Cyclic nucleotide-dependent inhibitory signaling interweaves with

activating pathways to determine platelet responses. Res Pract Thromb Haemost. 2018;2(3):558-71.

78518.Zhao L, Liu J, He C, Yan R, Zhou K, Cui Q, et al. Protein kinase A determines platelet life span786and survival by regulating apoptosis. J Clin Invest. 2017;127(12):4338-51.

All rights reserved. No reuse allowed without permission.

787 19. Fisch A, Michael-Hepp J, Meyer J, Darius H. Synergistic interaction of adenylate cyclase 788 activators and nitric oxide donor SIN-1 on platelet cyclic AMP. Eur J Pharmacol. 1995;289(3):455-61. 789 20. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor 790 prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. 791 21. Roka-Moiia Y, Walk R, Palomares DE, Ammann KR, Dimasi A, Italiano JE, et al. Platelet 792 Activation via Shear Stress Exposure Induces a Differing Pattern of Biomarkers of Activation versus 793 Biochemical Agonists. Thromb Haemost. 2020;120(5):776-92. 794 22. Shcherbina A, Remold-O'Donnell E. Role of caspase in a subset of human platelet activation 795 responses. Blood. 1999;93(12):4222-31. 796 Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V. Increased platelet phosphatidylserine 23. 797 exposure and caspase activation in chronic uremia. J Thromb Haemost. 2004;2(8):1275-81. 798 Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: 24. 799 mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol. 800 1989;73(2):235-40. 801 25. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its 802 differentiation from non-HIT thrombocytopenia. Thromb Haemost. 2016;116(5):813-22. 803 26. Rink TJ, Sage SO. Calcium signaling in human platelets. Annu Rev Physiol. 1990;52:431-49. 804 Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors 27. 805 GPVI and CLEC-2. J Clin Invest. 2019;129(1):12-23. 806 28. Barkalow KL, Falet H, Italiano JE, Jr., van Vugt A, Carpenter CL, Schreiber AD, et al. Role for 807 phosphoinositide 3-kinase in Fc gamma RIIA-induced platelet shape change. Am J Physiol Cell Physiol. 808 2003;285(4):C797-805. 809 29. Kunzelmann-Marche C, Freyssinet JM, Martinez MC. Regulation of phosphatidylserine 810 transbilayer redistribution by store-operated Ca2+ entry: role of actin cytoskeleton. J Biol Chem. 811 2001;276(7):5134-9. 812 30. Bergmeier W, Oh-Hora M, McCarl CA, Roden RC, Bray PF, Feske S. R93W mutation in Orai1 813 causes impaired calcium influx in platelets. Blood. 2009;113(3):675-8. 814 Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not 31. 815 fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity 816 of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. 817 Blood. 1997;90(7):2615-25. 818 32. Tomiyama Y, Kosugi S. Autoantigenic epitopes on platelet glycoproteins. Int J Hematol. 819 2005;81(2):100-5. 820 33. Schoenwaelder SM, Yuan Y, Josefsson EC, White MJ, Yao Y, Mason KD, et al. Two distinct 821 pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 822 2009;114(3):663-6. 823 34. Mattheij NJ, Gilio K, van Kruchten R, Jobe SM, Wieschhaus AJ, Chishti AH, et al. Dual 824 mechanism of integrin alphallbbeta3 closure in procoagulant platelets. J Biol Chem. 825 2013;288(19):13325-36. 826 Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin 35. 827 alphallbbeta3 adhesive function and thrombus growth. J Biol Chem. 2004;279(29):30697-706. 828 Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb 36. 829 Haemost. 2012;10(2):167-76.



ICU COVID-19

Figure 2.1.

Figure 2.1.





В



ICU COVID-19

ICU COVID-19





Figure 6.1.





В





Figure 7.1.



В







А

С





Figure 8.1.





В







+Forskolin

Figure 8.2. I-IV

Figure 9.1.







В





